Lisata Therapeutics, Inc. (FRA:8NE)

Lisata Therapeutics Statistics

Total Valuation

FRA:8NE has a market cap or net worth of EUR 15.25 million. The enterprise value is -1.31 million.

Market Cap	15.25M
Enterprise Value	-1.31M

Important Dates

The next estimated earnings date is Friday, February 27, 2026.

Earnings Date	Feb 27, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	8.82M
Shares Outstanding	n/a
Shares Change (YoY)	+3.87%
Shares Change (QoQ)	+1.55%
Owned by Insiders (%)	16.96%
Owned by Institutions (%)	8.38%
Float	7.32M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	16.72
PB Ratio	1.05
P/TBV Ratio	1.04
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	0.08
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	0.09

Financial Position

The company has a current ratio of 4.72

Current Ratio	4.72
Quick Ratio	4.42
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -72.17% and return on invested capital (ROIC) is -49.47%.

Return on Equity (ROE)	-72.17%
Return on Assets (ROA)	-41.86%
Return on Invested Capital (ROIC)	-49.47%
Return on Capital Employed (ROCE)	-116.80%
Revenue Per Employee	35,075
Profits Per Employee	-597,987
Employee Count	26
Asset Turnover	0.04
Inventory Turnover	n/a

Taxes

Income Tax	-819,913
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -35.50% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-35.50%
50-Day Moving Average	1.94
200-Day Moving Average	2.04
Relative Strength Index (RSI)	40.71
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	0.31

Income Statement

In the last 12 months, FRA:8NE had revenue of EUR 911,961 and -15.55 million in losses. Loss per share was -1.81.

Revenue	911,961
Gross Profit	911,961
Operating Income	-17.11M
Pretax Income	-16.37M
Net Income	-15.55M
EBITDA	-16.97M
EBIT	-17.11M
Loss Per Share	-1.81

Balance Sheet

The company has 16.19 million in cash and n/a in debt, giving a net cash position of 16.19 million.

Cash & Cash Equivalents	16.19M
Total Debt	n/a
Net Cash	16.19M
Net Cash Per Share	n/a
Equity (Book Value)	14.59M
Book Value Per Share	1.69
Working Capital	14.50M

Cash Flow

In the last 12 months, operating cash flow was -14.68 million and capital expenditures -23,864, giving a free cash flow of -14.71 million.

Operating Cash Flow	-14.68M
Capital Expenditures	-23,864
Free Cash Flow	-14.71M
FCF Per Share	n/a

Margins

Gross Margin	100.00%
Operating Margin	-1,876.54%
Pretax Margin	-1,794.77%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

FRA:8NE does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.87%
Shareholder Yield	-3.87%
Earnings Yield	-101.94%
FCF Yield	-96.43%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 15, 2022. It was a reverse split with a ratio of 0.0666666667.

Last Split Date	Sep 15, 2022
Split Type	Reverse
Split Ratio	0.0666666667

Scores

FRA:8NE has an Altman Z-Score of -35.32 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-35.32
Piotroski F-Score	1